Pfizer is Making Progress on a COVID-19 Vaccine: What We Know Now

As pharmaceutical companies worldwide race to find a vaccine for the novel Coronavirus, progress is being made at Pfizer.

The global pandemic has put the most brilliant minds on the planet to the test to come up with a vaccine. Back in May, pharmaceutical giant Pfizer announced that they would manufacture some of their COVID-19 trial vaccine in Kalamazoo. Promising developments are moving clinical trial to the next stage.

When will we get a vaccine?

Pfizer says, "companies expect to manufacture globally up to 100 million doses by the end of 2020 and potentially 1.3 billion doses by the end of 2021." That's if (and it's a big "if") regulatory approval and authorization is approved at the federal level.

Who will get it first?

Pfizer is "working with governments around the world to provide and distribute our vaccine, if approved. Once our vaccine is approved, those governments and local regulatory authorities will decide how the vaccine will be distributed."

How much will I have to pay?

Even though the company has "billions of dollars already invested in an effort to find a solution to this pandemic," they pledge to price the vaccine "in a way to help governments ensure there is little to no out-of-pocket costs for the vaccine for their populations."

The Kalamazoo manufacturing site is Pfizer's largest in the United States. You can read more about their progress in developing a potential COVID-19 vaccine here.